A dose-response study for I-125 prostate implants

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 1, 1998, Pages 101-108

  Stock, Richard G ^a   Stone, Nelson N ^a   Tabert, Andrea ^a   Iannuzzi, Christopher ^a   Dewyngaert, J Keith ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Dose response; Iodine I 125; Prostate cancer

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRACHYTHERAPY; DOSE RESPONSE; DOSIMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIATION DOSE; SCORING SYSTEM; TREATMENT OUTCOME;

BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 0032054704     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00006-6     Document Type: Article

References (34)

1. Hilaris B. S., Whitmore W. F., Batata M. A., Grabstald H. Radiation therapy and pelvic node dissection in the management of cancer of the prostate. AJR. 121:1974;832-838.
2. Marchese M. J., Hall E. J., Hilaris B. S. Clinical, physical and radiobiological aspects of encapsulated I-125 in radiation oncology. Endocur./Hypertherm. Oncol. 1:1985;67-82.
3. Orton C. G., Webber B. M. Time-dose factor (TDF) analysis of dose rate effects in permanent implant dosimetry. Int. J. Radiat. Oncol. Biol. Phys. 2:1977;55-60.
4. Hanks G. E., Asbell S. O., Krall J. M., Perez C. A., Doggett S., Rubin P. Outcome for lymph node dissection negative T1b, T2(A2-B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int. J. Radiat. Oncol. Biol. Phys. 21:1991;1099-1103.
5. Shipley W. U., Prout G. R., Coachman N. M., McManus P., Healy E. A., Althausen A. F. Radiation therapy for localized prostatic carcinoma The experience at the Massachusetts General Hospital (1973-1981) . Monogr. Natl. Cancer Inst. 7:1988;67-74.
6. Zagars G. K., von Eschenbach A. C., Johnson D. E., Oswald M. J. The role of radiation therapy in stages A2 and B carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 14:1988;701-709.
7. Kabalin J. N., Hodge K. K., McNeal J. E., Freiha F. S., Stamey T. A. Identification of residual cancer in the prostate following radiation therapy Role of transrectal ultrasound guided biopsy and prostate specific antigen . J. Urol. 142:1989;326-331.
8. Kiesling V. J., McAninch J. W., Goebel J. L., Agee R. E. External beam radiotherapy for adenocarcinoma of the prostate A clinical follow-up . J. Urol. 124:1980;851-854.
9. Zeitman A. K., Coen J. J., Shipley W. U., Willett C. G., Efrid J. T. Radical radiation therapy in the management of prostatic adenocarcinoma The initial prostate specific antigen value as a predictor of treatment outcome . J. Urol. 151:1994;640-645.
10. Anderson L. L. Spacing nomographs for interstitial implants of I-125 seeds. Med. Phys. 3:1976;48-51.
11. Stone N. N., Stock R. G., DeWyngaert J. K., Tabert A. Prostate brachytherapy Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry . Radiat. Oncol. Invest. 3:1995;185-195.
12. Stock R. G., Stone N. N., Wesson M. F., DeWyngaert J. K. A modifed technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;219-225.
13. Stock R. G., Stone N. N., Ianuzzi C., Unger P. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection Implications for patient selection in the radiotherapeutic management of prostate cancer . Int. J. Radiat. Oncol. Biol. Phys. 33:1995;815-821.
14. Nath R., Anderson L. L., Luxton G., Weaver K. A., Meigooni A. Dosimetry of interstitial brachytherapy sources Recommendations of the AAPM Radiation therapy Committee Task Force Group No. 43 . Med. Phys. 22:1995;209-234.
15. Kaplan E. L., Meier P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
16. Cox, D. R.; Oakes, D. Analysis of survival data. Chapman and Hall: 1984.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:1966;163-170.
18. Cox D. R Regression models and life tables . J. R. Stat. Soc. 34:1972;187-220.
19. Feinberg S. E. The analysis of cross-classified categorical data, 2nd ed. 1980;MIT Press, Cambridge, MA.
20. Hanks G. E., Martz K. L., Diamond J. J. The effect of dose on local control of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 15:1988;1299-1305.
21. Laramore G. E., Krall J. M., Thomas F. J., Griffith T. W., Maor M. H., Hendrickson F. R. Fast neutron radiotherapy for locally advanced prostate cancer. Results of an RTOG randomized study. Int. J. Radiat. Oncol. Biol. Phys. 11:1985;1621-1627.
22. Hanks G. E., Lee W. R., Hanlon A. L., Hunt M., Kaplan E., Epstein B. E., Movsas B., Schultheiss T. E. Conformal technique dose escalation for prostate cancer Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml . Int. J. Radiat. Oncol. Biol. Phys. 35:1996;861-868.
23. Roach M., Meehan S., Kroll S., Weil M., Ryu J., Small E. J., Margolis L. W., Presti J., Carroll P. C., Phillips T. L. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J. of Urol. 156:1996;1719-1723.
24. Zelefsky M. J., Leibel S. A., Kelson S., Fuks Z. Impact of radiation dose on achieving a nadir PSA level after 3-dimensional conformal radiotherapy for patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;196.
25. Fuks Z., Leibel S. A., Wallner K. E., Begg C. B., Fair W. R., Anderson L. L., Hilaris B. S., Whitmore W. F. The effect of local control on metastatic dissemination in carcinoma of the prostate Long-term results in pateints treated with I-125 implantation . Int. J. Radiat. Oncol. Biol. Phys. 21:1991;537-547.
26. Kim J. H., Hilaris B. Iodine 125 source in interstitial tumor therapy. Clinical and biological considerations. AJR. 123:1975;163-169.
27. Stone N. N., Forman J. D., Sogani P. C., Hilaris B. S., Whitmore W. F., Fair W. R. Transrectal ultrasonography and I-125 implantation in patients with prostate cancer. J. Urol. 139:1988;604A.
28. Prestidge B. R., Hoak D. C., Grimm P. D., Ragde H., Cavanagh W., Blasko J. C. Posttreatment biopsy results following interstitial brachytherapy in early stage prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;31-39.
29. Roy J. N., Wallner K. E., Harrington P. J., Ling C. C., Anderson L. L. A CT-based evaluation method for permanent implants Applications to prostate . Int. J. Radiat. Oncol. Biol. Phys. 26:1993;163-169.
30. Stock R. G., Stone N. N., DeWyngaert J. K., Lavagnini P., Unger P. D. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer. 77:1996;2386-2392.
31. Stock R. G., Stone N. N. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin. Surg. Oncol. 13:1997;454-460.
32. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J. Clin. Oncol. 14:1996;449-453.
33. Blasko J. C., Wallner K., Grimm P. D., Ragde H. PSA based disease control following ultrasound guided I-125 implantation for stage T1/T2 prostatic carcinoma. J. Urol. 154:1995;1096-1099.
34. Luse R. W., Blasko J., Grimm P. A method for implementing the American Association of Physicists in Medicine Task Force Group-43 dosimetry recommendations for I-125 transperineal prostate seed implants on commercial treatment planning systems. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;737-741.